JP7577428B2 - ジアセレインまたはレインの局所製剤およびその使用 - Google Patents

ジアセレインまたはレインの局所製剤およびその使用 Download PDF

Info

Publication number
JP7577428B2
JP7577428B2 JP2017568131A JP2017568131A JP7577428B2 JP 7577428 B2 JP7577428 B2 JP 7577428B2 JP 2017568131 A JP2017568131 A JP 2017568131A JP 2017568131 A JP2017568131 A JP 2017568131A JP 7577428 B2 JP7577428 B2 JP 7577428B2
Authority
JP
Japan
Prior art keywords
composition
diacerein
skin
rhein
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522875A5 (enExample
JP2018522875A (ja
Inventor
ブラウン・ザ・サード，カール・オスカー
チェン，チー－クワン
リー，ジン－イー
ルゥ，ウェイ－シュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWi Biotechnology Inc
Original Assignee
TWi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWi Biotechnology Inc filed Critical TWi Biotechnology Inc
Publication of JP2018522875A publication Critical patent/JP2018522875A/ja
Publication of JP2018522875A5 publication Critical patent/JP2018522875A5/ja
Priority to JP2022125318A priority Critical patent/JP7578651B2/ja
Priority to JP2024122108A priority patent/JP2024164022A/ja
Application granted granted Critical
Publication of JP7577428B2 publication Critical patent/JP7577428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017568131A 2015-07-01 2016-06-30 ジアセレインまたはレインの局所製剤およびその使用 Active JP7577428B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022125318A JP7578651B2 (ja) 2015-07-01 2022-08-05 ジアセレインまたはレインの局所製剤およびその使用
JP2024122108A JP2024164022A (ja) 2015-07-01 2024-07-29 ジアセレインまたはレインの局所製剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187743P 2015-07-01 2015-07-01
US62/187,743 2015-07-01
PCT/US2016/040287 WO2017004319A1 (en) 2015-07-01 2016-06-30 Diacerein or rhein topical formulations and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022125318A Division JP7578651B2 (ja) 2015-07-01 2022-08-05 ジアセレインまたはレインの局所製剤およびその使用
JP2024122108A Division JP2024164022A (ja) 2015-07-01 2024-07-29 ジアセレインまたはレインの局所製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2018522875A JP2018522875A (ja) 2018-08-16
JP2018522875A5 JP2018522875A5 (enExample) 2021-01-14
JP7577428B2 true JP7577428B2 (ja) 2024-11-05

Family

ID=57609470

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017568131A Active JP7577428B2 (ja) 2015-07-01 2016-06-30 ジアセレインまたはレインの局所製剤およびその使用
JP2022125318A Active JP7578651B2 (ja) 2015-07-01 2022-08-05 ジアセレインまたはレインの局所製剤およびその使用
JP2024122108A Pending JP2024164022A (ja) 2015-07-01 2024-07-29 ジアセレインまたはレインの局所製剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022125318A Active JP7578651B2 (ja) 2015-07-01 2022-08-05 ジアセレインまたはレインの局所製剤およびその使用
JP2024122108A Pending JP2024164022A (ja) 2015-07-01 2024-07-29 ジアセレインまたはレインの局所製剤およびその使用

Country Status (12)

Country Link
US (1) US9744131B2 (enExample)
EP (1) EP3316879A4 (enExample)
JP (3) JP7577428B2 (enExample)
KR (1) KR102702557B1 (enExample)
CN (2) CN107921013A (enExample)
AU (2) AU2016287636B2 (enExample)
CA (1) CA2990948C (enExample)
HK (1) HK1249057A1 (enExample)
IL (1) IL256585B (enExample)
MX (1) MX373702B (enExample)
TW (1) TWI723032B (enExample)
WO (1) WO2017004319A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180037261A (ko) * 2015-08-17 2018-04-11 티더블유아이 바이오테크놀로지 인코포레이티드 Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체
EP3570835B1 (en) * 2017-01-19 2023-08-09 TWI Biotechnology, Inc. Diacerein for preventing or treating immunoinflammatory dermal disorders
CN106692037B (zh) * 2017-01-24 2020-02-18 中南大学湘雅医院 大黄酸超分子水凝胶及其制备方法和应用
CN107823126B (zh) * 2017-12-04 2020-03-24 广东药科大学 双醋瑞因注射型温敏凝胶及其制备方法
CN111265508B (zh) * 2018-12-05 2022-03-25 中检科医药科技(北京)集团有限公司 双醋瑞因在制备抗病毒药物及治疗病毒感染中的用途
CN109758421A (zh) * 2019-03-27 2019-05-17 毕波 一种蓝氧抗菌灭毒软膏及其制备方法
US20220265577A1 (en) * 2019-08-03 2022-08-25 Venkateswarlu Vobalaboina Process for the preparation of anthraquinone topical formulation
CN110585120B (zh) * 2019-10-08 2020-11-27 中南大学 一种可注射双醋瑞因水凝胶及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124358A (en) 1996-12-23 2000-09-26 Mazal Pharmaceutique (Sarl) Pharmaceutical composition containing rhein or diacerhein with improved bioavailability
WO2009133430A1 (en) 2008-04-30 2009-11-05 Wockhardt Research Centre Topical compositions of rhein or diacerein
US20100285114A1 (en) 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
US20130156857A1 (en) 2008-10-28 2013-06-20 Twi Biotechnology, Inc. Pharmaceutical Compositions Containing Diacerein
US20140163217A1 (en) 2010-07-29 2014-06-12 Universite De Geneve Process for the esterification of hyaluronic acid with hydrophobic organic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4018764B2 (ja) * 1996-10-18 2007-12-05 正規 小菅 津液改善用皮膚外用剤
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20090093509A1 (en) * 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
FR2949044B1 (fr) * 2009-08-12 2021-05-07 Expanscience Lab Composition comprenant une fraction d'insaponifiable
MX2012011517A (es) 2010-04-08 2012-11-29 Twi Biotechnology Inc El uso de diacereina como una terapia adyuvante para diabetes.
JP6012639B2 (ja) 2011-03-11 2016-10-25 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124358A (en) 1996-12-23 2000-09-26 Mazal Pharmaceutique (Sarl) Pharmaceutical composition containing rhein or diacerhein with improved bioavailability
US20100285114A1 (en) 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
WO2009133430A1 (en) 2008-04-30 2009-11-05 Wockhardt Research Centre Topical compositions of rhein or diacerein
US20130156857A1 (en) 2008-10-28 2013-06-20 Twi Biotechnology, Inc. Pharmaceutical Compositions Containing Diacerein
US20140163217A1 (en) 2010-07-29 2014-06-12 Universite De Geneve Process for the esterification of hyaluronic acid with hydrophobic organic compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ｗａｌｌｙ ｅｔ ａｌ．， Ｏｒｐｈａｎｅｔ Ｊｏｕｒｎａｌ ｏｆ Ｒａｒｅ Ｄｉｓｅａｓｅｓ，２０１３年，８：６９，ＵＲＬ，ｈｔｔｐｓ：／／ｏｊｒｄ．ｂｉｏｍｅｄｃｅｎｔｒａｌ．ｃｏｍ／ａｒｔｉｃｌｅｓ／１０．１１８６／１７５０－１１７２－８－６９
フレグランスジャーナル，２００５年，臨時増刊，第１９号，ｐ．４５－５１
新化粧品ハンドブック，２００６年，ｐ．２４－３０
日本香粧品学会誌，２０１４年，Ｖｏｌ．３８ Ｎｏ．２，ｐｐ．９６－１０２
病院薬学，１９８２年，Ｖｏｌ．８ Ｎｏ．３，ｐｐ．１７５－１８１
調剤の疑問解消！，日経ＤＩ，２０１２年，１２月号，ＵＲＬ：［ｈｔｔｐｓ：／／ｍｅｄｅｉｃａｌ．ｎｉｋｋｅｉｂｐ．ｃｏ．ｊｐ／ｌｅａｆ／ａｌｌ／ｄｉ／ｄｉｇｉｔａｌ／２０１２１２／５２８０４４．ｈｔｍｌ］

Also Published As

Publication number Publication date
EP3316879A4 (en) 2019-01-23
CN107921013A (zh) 2018-04-17
AU2016287636A1 (en) 2018-02-08
US20170000732A1 (en) 2017-01-05
IL256585B (en) 2021-05-31
JP2018522875A (ja) 2018-08-16
CA2990948C (en) 2024-09-10
WO2017004319A1 (en) 2017-01-05
JP2022169600A (ja) 2022-11-09
JP7578651B2 (ja) 2024-11-06
TW201717932A (zh) 2017-06-01
EP3316879A1 (en) 2018-05-09
CN117482078A (zh) 2024-02-02
JP2024164022A (ja) 2024-11-26
MX373702B (es) 2020-05-07
US9744131B2 (en) 2017-08-29
KR20180023965A (ko) 2018-03-07
TWI723032B (zh) 2021-04-01
MX2018000264A (es) 2018-05-23
AU2021229177A1 (en) 2021-10-07
CA2990948A1 (en) 2017-01-05
KR102702557B1 (ko) 2024-09-03
AU2021229177B2 (en) 2023-11-23
IL256585A (en) 2018-02-28
AU2016287636B2 (en) 2021-09-16
HK1249057A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
JP7578651B2 (ja) ジアセレインまたはレインの局所製剤およびその使用
JP2012507511A (ja) 少なくとも２種の透過増強剤を組み合わせて含む局所用組成物
JP5052558B2 (ja) ゲル軟膏
KR20230122024A (ko) 타피나로프의 겔, 연고, 및 폼 제형 및 사용 방법
WO2014168228A1 (ja) 局所用組成物
EP3236938B1 (en) Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol
JP4372398B2 (ja) フリーラジカル性疾患用外用剤
US10512625B2 (en) Diacerein or rhein topical formulations and uses thereof
US10154984B2 (en) Diacerein or Rhein topical formulations and uses thereof
CN100490899C (zh) 薰草菌素的药用组合物
EP1700597A1 (en) Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application
HK1092699B (en) Pharmaceutical compositions of lavendustin
WO2017116273A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200820

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220805

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220830

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221005

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221011

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221028

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241023

R150 Certificate of patent or registration of utility model

Ref document number: 7577428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150